Anticoagulation Therapy for Deep Vein Thrombosis

Initial Treatment

The American Society of Clinical Oncology recommends dalteparina 200 UI/kg once daily, enoxaparina 1 mg/kg every 12 hours or 1.5 mg/kg once daily, or tinzaparina 175 UI/kg once daily for the initial treatment of deep vein thrombosis 1, 2, 3
The American College of Chest Physicians suggests unfractionated heparin with a bolus dose of 80 UI/kg intravenously, followed by 18 UI/kg/hour intravenously, adjusting the dose according to the activated partial thromboplastin time (aPTT) 2, 3
For patients with a body weight less than 50 kg, 50-100 kg, or greater than 100 kg, fondaparinux doses are 5.0 mg, 7.5 mg, and 10 mg once daily, respectively 2, 3

The American Society of Clinical Oncology recommends dalteparina 200 UI/kg once daily for the first month, then 150 UI/kg once daily, or enoxaparina 1.5 mg/kg once daily or 1 mg/kg every 12 hours for long-term treatment 2, 3
The American College of Chest Physicians suggests rivaroxaban 15 mg every 12 hours for 21 days, followed by 20 mg once daily with food, or apixaban 10 mg twice daily for 7 days, then 5 mg twice daily 3, 4
For patients requiring vitamin K antagonist therapy, warfarina dose should be adjusted to maintain an international normalized ratio (INR) between 2.0 and 3.0 1, 2

In patients with renal insufficiency (creatinine clearance less than 30 mL/min), unfractionated heparin is preferred due to its hepatic elimination 1, 6
For patients with cancer, oral factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) are preferred over low molecular weight heparin 4
The duration of treatment for deep vein thrombosis depends on the presence of transient or persistent risk factors, with a minimum of 3 months for transient risk factors and extended treatment for persistent risk factors or active cancer 4, 7

Outpatient treatment with low molecular weight heparin is safe and effective for selected patients with deep vein thrombosis 5
Hospitalization is recommended for patients with extensive iliofemoral deep vein thrombosis, significant comorbidities, or high risk of bleeding 5

Low molecular weight heparin is preferred over unfractionated heparin for initial treatment due to its higher efficacy, lower risk of heparin-induced thrombocytopenia, and ease of administration 1, 5
Direct oral anticoagulants are preferred over vitamin K antagonists for the treatment phase (first 3 months) due to their safety and efficacy profile 4
Laboratory monitoring is not necessary with low molecular weight heparin or direct oral anticoagulants in most patients 6